Cytochrome P450 3A4 Inhibitors and Drug Interactions
Strong CYP3A4 inhibitors include azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole) and HIV protease inhibitors (ritonavir, nelfinavir, indinavir, saquinavir, atazanavir), while moderate inhibitors include macrolide antibiotics (clarithromycin, erythromycin, telithromycin), diltiazem, verapamil, and fluconazole.
Strong CYP3A4 Inhibitors
The most potent CYP3A4 inhibitors are those that also inhibit P-glycoprotein (P-gp), creating dual inhibition that significantly increases drug exposure 1:
Azole Antifungals
- Ketoconazole (400 mg once daily): Increases substrate drug AUC by approximately 2.5-fold and Cmax by 1.7-fold 1
- Itraconazole, voriconazole, posaconazole: Similar potency to ketoconazole; contraindicated with many CYP3A4 substrates 1, 2, 3
HIV Protease Inhibitors
- Ritonavir (600 mg twice daily): Increases substrate drug AUC by approximately 2.5-fold 1
- Nelfinavir, indinavir, saquinavir, atazanavir: All strong CYP3A4 inhibitors requiring dose adjustments or contraindication with sensitive substrates 4, 2, 5
Moderate CYP3A4 Inhibitors
These inhibitors cause less dramatic but clinically significant increases in drug exposure 6:
Macrolide Antibiotics
- Clarithromycin (500 mg twice daily): Increases substrate AUC by 1.5-fold and Cmax by 1.4-fold 1
- Erythromycin (500 mg three times daily): Increases substrate AUC and Cmax by 1.3-fold 1
- Telithromycin: Similar potency to clarithromycin 6
Calcium Channel Blockers
- Diltiazem: Increases substrate AUC by approximately 2.2-fold 7, 8
- Verapamil: Similar interaction profile to diltiazem 8, 9
Antifungals
Dose Adjustment Strategies for CYP3A4-Metabolized Drugs
With Strong CYP3A4 Inhibitors
For drugs with narrow therapeutic indices, avoid concomitant use entirely or reduce the substrate drug dose by 50-75% 1, 11:
- Rivaroxaban: Avoid combination; if unavoidable, not recommended for use 1
- Apixaban: Reduce dose by 50% if on 5-10 mg twice daily regimens; avoid with 2.5 mg twice daily dosing 11
- Daclatasvir: Reduce dose from 60 mg to 30 mg once daily 6, 12
- Ivabradine: Contraindicated with strong CYP3A4 inhibitors 4
With Moderate CYP3A4 Inhibitors
Reduce substrate drug doses by 25-50% or monitor closely for adverse effects 1, 13:
- Rivaroxaban: Use with caution; monitor for bleeding 1
- Eplerenone: Do not exceed 25 mg daily 5
- Guanfacine extended-release: Decrease to 50% of usual target dose 13
- Daclatasvir: Reduce to 30 mg once daily with clarithromycin, erythromycin, or telithromycin 6
CYP3A4 Inducers
Strong inducers significantly reduce substrate drug exposure and should generally be avoided 1, 3:
Strong Inducers
- Rifampin: Decreases substrate AUC by 50% 1
- Carbamazepine, phenytoin, phenobarbital: All potent inducers requiring dose increases of substrates or alternative therapy 2, 3, 10
- St. John's wort: Unpredictable induction; avoid combination 1, 2, 3
Dose Adjustments with Inducers
- Daclatasvir: Increase from 60 mg to 90 mg once daily with efavirenz 6, 12
- Dasatinib: Consider dose increase; monitor for efficacy 2
- Guanfacine extended-release: Titrate up to double the usual target dose over 1-2 weeks 13
Critical Clinical Considerations
Dual inhibition of both CYP3A4 and P-glycoprotein produces the most clinically significant interactions, often requiring contraindication rather than dose adjustment 1, 11. This is particularly important for:
- Direct oral anticoagulants (rivaroxaban, apixaban, edoxaban) 11
- Immunosuppressants (tacrolimus, cyclosporine) 10
- Certain antiarrhythmics and cardiovascular agents 4, 14
Mechanism-based inhibition by drugs like clarithromycin, erythromycin, and ritonavir causes irreversible enzyme inactivation, leading to prolonged effects that persist beyond drug discontinuation 8, 9. This requires extended monitoring periods after stopping the inhibitor.
Renal impairment significantly amplifies CYP3A4 inhibitor effects, particularly for drugs with renal elimination pathways 11. In patients with creatinine clearance <50 mL/min receiving strong CYP3A4 and P-gp inhibitors, consider alternative therapy rather than dose adjustment 11.